The Application Value of Spectral CT in the Accurate Staging of Breast Cancer

Yunnan Cancer Hospital

Status: Not yet enrolling

Conditions: Breast Adenocarcinoma

Treatments: Diagnostic Test: To explore the value of spectral CT in the diagnosis and treatment of breast cancer

Study type: Interventional

Funder types: Other

Identifiers

NCT06977412

KYLX2025-105

Details and patient eligibility

About

Spectral CT was used to prospectively collect medical images and clinical data related to breast cancer, evaluate the effect of image quality in the diagnosis of breast cancer, and evaluate the application value in the accurate staging of breast cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.

Enrollment: 150 estimated patients

Sex: Female

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• (a) Chest quark energy spectrum CT examination was performed within 1 week before treatment
• (b) Age ≥ 18
• (c) Suspected breast cancer patients
• (d) Patients who signed informed consent

Exclusion criteria

• (a) Severe cardiac, pulmonary and renal insufficiency
• (b) Allergic to iodine contrast media
• (c) Unable to cooperate to complete CT examination
• (d) Quark spectrum CT image is poor and cannot be used
• (e) Male, pregnant and lactating female
• (f) Combined with other tumor history
• (g) Incomplete clinical and pathological data
• (h) Pathologically confirmed non breast cancer

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

150 participants in 1 patient group

The application value of spectral CT in the accurate staging of breast cancer

Experimental group

Description:

Prospectively collect medical images and clinical data related to breast cancer using Philips Quark CT equipment, and evaluate the diagnostic accuracy and clinical application value in the accurate staging of breast cancer. Patients diagnosed with breast cancer in Yunnan Provincial Cancer Hospital from April 2025 to May 2026 were consecutively included, and after scanning with Philips Quark CT, the TNM stage of breast cancer patients was assessed by two radiologists, and finally statistical analysis was performed.

Treatment:

Diagnostic Test: To explore the value of spectral CT in the diagnosis and treatment of breast cancer